{"id":133588,"date":"2026-06-29T14:37:11","date_gmt":"2026-06-29T09:07:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=133588"},"modified":"2026-06-29T14:37:13","modified_gmt":"2026-06-29T09:07:13","slug":"concord-biotech-q1-results-fy27","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/","title":{"rendered":"Concord Biotech Q1 Results FY27: What to Expect"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Concord Biotech Q1 Results FY27: Revenue Rs 193 Cr (-5.6% YoY) | PAT Rs 32 Cr (-26.7% YoY), Uniresearch estimate.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/concordbio\/concord-biotech-ltd-share-price-today\">Concord Biotech<\/a> Q1 Results FY27 prediction is based on Screener.in consolidated quarterly financials for the Q1 FY26 base quarter, with the Uniresearch trailing-growth model applied to project the Q1 FY27 estimate. Concord Biotech reported Revenue of Rs 204 Cr and PAT of Rs 44 Cr in Q1 FY26, forming the base for the Concord Biotech Q1 Results FY27 forecast of Rs 193 Cr Revenue and Rs 32 Cr PAT. Prepared by Kunal Singla, Associate Director.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=concordbio-q1-results\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Concord_Biotech_Q1_Results_FY27_Uniresearch_Prediction\" title=\"Concord Biotech Q1 Results FY27: Uniresearch Prediction\">Concord Biotech Q1 Results FY27: Uniresearch Prediction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Q4_FY26_Performance_Base_for_the_Prediction\" title=\"Q4 FY26 Performance: Base for the Prediction\">Q4 FY26 Performance: Base for the Prediction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Uniresearch_Estimate_Behind_the_Concord_Biotech_Q1_Results_FY27_Projection\" title=\"Uniresearch Estimate Behind the Concord Biotech Q1 Results FY27 Projection\">Uniresearch Estimate Behind the Concord Biotech Q1 Results FY27 Projection<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Key_Watchpoints_for_the_Concord_Biotech_Q1_Results_FY27\" title=\"Key Watchpoints for the Concord Biotech Q1 Results FY27\">Key Watchpoints for the Concord Biotech Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Revenue_vs_Estimate\" title=\"Revenue vs Estimate\">Revenue vs Estimate<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#PAT_Margin_Sustainability\" title=\"PAT Margin Sustainability\">PAT Margin Sustainability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Management_Commentary_and_Full-Year_FY27_Guidance\" title=\"Management Commentary and Full-Year FY27 Guidance\">Management Commentary and Full-Year FY27 Guidance<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Risks_to_the_Concord_Biotech_Q1_Results_FY27_Prediction\" title=\"Risks to the Concord Biotech Q1 Results FY27 Prediction\">Risks to the Concord Biotech Q1 Results FY27 Prediction<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Below-Estimate_Revenue_Growth\" title=\"Below-Estimate Revenue Growth\">Below-Estimate Revenue Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#PAT_Pressure_from_Costs_or_Provisions\" title=\"PAT Pressure from Costs or Provisions\">PAT Pressure from Costs or Provisions<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#External_and_Macro_Environment\" title=\"External and Macro Environment\">External and Macro Environment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Concord_Biotech_Q1_Results_FY27_Sector_Growth_Drivers\" title=\"Concord Biotech Q1 Results FY27: Sector Growth Drivers\">Concord Biotech Q1 Results FY27: Sector Growth Drivers<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Domestic_Formulation_Growth\" title=\"Domestic Formulation Growth\">Domestic Formulation Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Regulated_Market_Export_Pipeline\" title=\"Regulated Market Export Pipeline\">Regulated Market Export Pipeline<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Concord_Biotech_Q1_Results_FY27_Conclusion\" title=\"Concord Biotech Q1 Results FY27: Conclusion\">Concord Biotech Q1 Results FY27: Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#Frequently_Asked_Questions_on_Concord_Biotech_Q1_Results_FY27\" title=\"Frequently Asked Questions on Concord Biotech Q1 Results FY27\">Frequently Asked Questions on Concord Biotech Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#What_is_the_Uniresearch_prediction_for_Concord_Biotech_Q1_Results_FY27\" title=\"What is the Uniresearch prediction for Concord Biotech Q1 Results FY27?\">What is the Uniresearch prediction for Concord Biotech Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#What_growth_rate_assumptions_are_used_in_the_Uniresearch_estimate_for_Concord_Biotech_Q1_Results_FY27\" title=\"What growth rate assumptions are used in the Uniresearch estimate for Concord Biotech Q1 Results FY27?\">What growth rate assumptions are used in the Uniresearch estimate for Concord Biotech Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#What_were_the_Q4_FY26_actuals_behind_the_Concord_Biotech_Q1_Results_FY27_projection\" title=\"What were the Q4 FY26 actuals behind the Concord Biotech Q1 Results FY27 projection?\">What were the Q4 FY26 actuals behind the Concord Biotech Q1 Results FY27 projection?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#How_reliable_is_the_Concord_Biotech_Q1_Results_FY27_Uniresearch_prediction\" title=\"How reliable is the Concord Biotech Q1 Results FY27 Uniresearch prediction?\">How reliable is the Concord Biotech Q1 Results FY27 Uniresearch prediction?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#What_base_data_is_used_for_the_Concord_Biotech_Q1_Results_FY27_Uniresearch_projection\" title=\"What base data is used for the Concord Biotech Q1 Results FY27 Uniresearch projection?\">What base data is used for the Concord Biotech Q1 Results FY27 Uniresearch projection?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#What_are_the_key_risks_to_the_Concord_Biotech_Q1_Results_FY27_estimate\" title=\"What are the key risks to the Concord Biotech Q1 Results FY27 estimate?\">What are the key risks to the Concord Biotech Q1 Results FY27 estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-q1-results-fy27\/#When_will_Concord_Biotech_declare_the_actual_Concord_Biotech_Q1_Results_FY27_data\" title=\"When will Concord Biotech declare the actual Concord Biotech Q1 Results FY27 data?\">When will Concord Biotech declare the actual Concord Biotech Q1 Results FY27 data?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Concord_Biotech_Q1_Results_FY27_Uniresearch_Prediction\"><\/span><strong>Concord Biotech Q1 Results FY27: Uniresearch Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse;\">\n<thead>\n<tr style=\"background: #EBF3FB;\">\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: left;\">Metric<\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">Q1 FY26 Actual<\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">Q1 FY27 Uniresearch Prediction<\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Revenue (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">204<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\"><strong>193<\/strong><\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">-5.6%<\/td>\n<\/tr>\n<tr style=\"background: #FFFFFF;\">\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">PAT (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">44<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\"><strong>32<\/strong><\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">-26.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"font-size: 12px; color: #666;\"><em>Source: Q1 FY26 actuals from Screener.in consolidated quarterly financial data. Q1 FY27 prediction for Concord Biotech applies Uniresearch trailing growth rates (Revenue -5.6%, PAT -26.7%) to Q1 FY26 verified actuals.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Concord Biotech Live on Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q4_FY26_Performance_Base_for_the_Prediction\"><\/span><strong>Q4 FY26 Performance: Base for the Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <a href=\"https:\/\/univest.in\/stocks\/concordbio\/concord-biotech-ltd-share-price-today\">Concord Biotech<\/a> Q1 Results FY27 prediction is anchored on Q4 FY26 consolidated Revenue of Rs 326 Cr and PAT of Rs 88 Cr per quarterly financial data. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 FY27 Uniresearch projection.<\/p>\n<p>The sequential comparison also provides useful context. Q4 FY26 Revenue of Rs 326 Cr reflects year-end execution cycles that may not repeat equally in Q1 FY27. The more meaningful benchmark is the year-on-year comparison against Q1 FY26 Revenue of Rs 204 Cr, where the Uniresearch estimate targets -5.6% growth. Both reads should be monitored when the actual Q1 FY27 numbers are declared.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Uniresearch_Estimate_Behind_the_Concord_Biotech_Q1_Results_FY27_Projection\"><\/span><strong>Uniresearch Estimate Behind the Concord Biotech Q1 Results FY27 Projection<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Concord Biotech Q1 Results FY27 prediction is derived from Uniresearch trailing analysis, which estimates Q1 FY27 Revenue growth of -5.6% and PAT growth of -26.7% year-on-year. Uniresearch applies these trailing growth rates to Q1 FY26 actuals to arrive at the Q1 FY27 projection of Rs 193 Cr Revenue and Rs 32 Cr PAT.<\/p>\n<p>The Q1 FY27 estimation methodology for Concord Biotech is worth clarifying for investors. Uniresearch applies full-year FY27 trailing growth rates (-5.6% Revenue, -26.7% PAT) uniformly to Q1 FY26 verified actuals to derive the quarterly projection. This approach assumes the quarterly trajectory broadly mirrors the full-year trend direction. Intra-year seasonality and one-time events can cause divergence. Treat this Q1 FY27 Uniresearch estimate for Concord Biotech as a directional benchmark, not a point forecast.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=concordbio-q1-overview\"><strong>Get Expert Stock Picks on Univest<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Watchpoints_for_the_Concord_Biotech_Q1_Results_FY27\"><\/span><strong>Key Watchpoints for the Concord Biotech Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_vs_Estimate\"><\/span><strong>Revenue vs Estimate<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Whether Concord Biotech Q1 Results FY27 Revenue delivers in line with the Rs 193 Cr Uniresearch estimate (-5.6% YoY). Q4 FY26 Revenue was Rs 326 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Margin_Sustainability\"><\/span><strong>PAT Margin Sustainability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PAT of Rs 32 Cr (-26.7% YoY) is the Concord Biotech Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 88 Cr. Margin stability signals operating leverage.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Management_Commentary_and_Full-Year_FY27_Guidance\"><\/span><strong>Management Commentary and Full-Year FY27 Guidance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Beyond Q1 FY27 headline numbers, Concord Biotech&#8217;s management commentary will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation. A confident outlook post an in-line result could support re-rating.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_the_Concord_Biotech_Q1_Results_FY27_Prediction\"><\/span><strong>Risks to the Concord Biotech Q1 Results FY27 Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Below-Estimate_Revenue_Growth\"><\/span><strong>Below-Estimate Revenue Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>If actual Q1 FY27 Revenue underperforms the -5.6% growth target, the Rs 193 Cr prediction would be revised downward.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Pressure_from_Costs_or_Provisions\"><\/span><strong>PAT Pressure from Costs or Provisions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>One-time charges, higher input costs, or elevated provisions could push PAT below Rs 32 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"External_and_Macro_Environment\"><\/span><strong>External and Macro Environment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Q1 FY27 performance is also exposed to macro-level risks including global commodity price movements, rupee-dollar volatility, domestic interest rate changes, and FII\/DII sentiment shifts. A deteriorating macro environment in Q1 FY27 could create downside risk even if company-specific execution remains on track.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Concord_Biotech_Q1_Results_FY27_Sector_Growth_Drivers\"><\/span><strong>Concord Biotech Q1 Results FY27: Sector Growth Drivers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sector positioning in the pharmaceuticals and life sciences sector. The following tailwinds and headwinds will shape the result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Domestic_Formulation_Growth\"><\/span><strong>Domestic Formulation Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s domestic pharma market grows at 8-10% annually, led by chronic therapies and branded generics.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regulated_Market_Export_Pipeline\"><\/span><strong>Regulated Market Export Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA-approved facilities and a growing ANDA pipeline offer incremental export revenues.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Use Univest Screener to Track Concord Biotech Live<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Concord_Biotech_Q1_Results_FY27_Conclusion\"><\/span><strong>Concord Biotech Q1 Results FY27: Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Concord Biotech Q1 Results FY27 Uniresearch projection of Revenue Rs 193 Cr and PAT Rs 32 Cr is derived from trailing growth rates applied to Q1 FY26 actuals. Track Concord Biotech live on the Univest Screener for real-time updates.<\/p>\n<p>Once the actual Q1 FY27 result for Concord Biotech is declared, compare it directly against the Uniresearch estimate to assess beat, meet, or miss. Use Univest research and screener tools to stay updated post the result announcement and to track any revision to the full-year FY27 outlook.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for live Q1 FY27 result alerts.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Revenue and PAT actuals sourced from Screener.in consolidated quarterly financial data. Q1 FY27 projections are derived from Uniresearch trailing growth rates applied to Q1 FY26 actuals. These are Uniresearch trailing estimates, not guaranteed outcomes. Investments are subject to market risk. For educational purposes only. SEBI RA INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Concord_Biotech_Q1_Results_FY27\"><\/span><strong>Frequently Asked Questions on Concord Biotech Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Uniresearch_prediction_for_Concord_Biotech_Q1_Results_FY27\"><\/span><strong>What is the Uniresearch prediction for Concord Biotech Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Uniresearch projects Q1 FY27 Revenue for Concord Biotech at Rs 193 Cr (-5.6% YoY) and PAT at Rs 32 Cr (-26.7% YoY), based on trailing analysis of Q1 FY26 actuals. Q1 FY26 Revenue was Rs 204 Cr and PAT Rs 44 Cr. Treat as directional estimate.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_growth_rate_assumptions_are_used_in_the_Uniresearch_estimate_for_Concord_Biotech_Q1_Results_FY27\"><\/span><strong>What growth rate assumptions are used in the Uniresearch estimate for Concord Biotech Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Uniresearch estimate applies trailing YoY growth rates (Revenue -5.6%, PAT -26.7%) derived from historical quarterly data to Q1 FY26 actuals (Revenue Rs 204 Cr, PAT Rs 44 Cr). These are directional estimates, not guarantees.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Q4_FY26_actuals_behind_the_Concord_Biotech_Q1_Results_FY27_projection\"><\/span><strong>What were the Q4 FY26 actuals behind the Concord Biotech Q1 Results FY27 projection?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Q4 FY26 consolidated Revenue was Rs 326 Cr and PAT was Rs 88 Cr. These Q4 FY26 actuals serve as the most recent sequential reference alongside the Q1 FY26 base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_reliable_is_the_Concord_Biotech_Q1_Results_FY27_Uniresearch_prediction\"><\/span><strong>How reliable is the Concord Biotech Q1 Results FY27 Uniresearch prediction?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Q1 Results FY27 estimate is a Uniresearch trailing projection, not a guaranteed outcome. Actual results may differ due to macro conditions, seasonal variation, and company-specific execution. Use the projection as a directional benchmark and compare against declared actuals on the Univest Screener.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_base_data_is_used_for_the_Concord_Biotech_Q1_Results_FY27_Uniresearch_projection\"><\/span><strong>What base data is used for the Concord Biotech Q1 Results FY27 Uniresearch projection?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Q1 FY27 projection for Concord Biotech uses Q1 FY26 consolidated actuals (Revenue Rs 204 Cr, PAT Rs 44 Cr) from Screener.in quarterly data. Trailing growth rates (-5.6% Revenue, -26.7% PAT) are applied to derive the Q1 FY27 estimate.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Concord_Biotech_Q1_Results_FY27_estimate\"><\/span><strong>What are the key risks to the Concord Biotech Q1 Results FY27 estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Q1 Results FY27 estimate for Concord Biotech include usfda regulatory risk, us generic pricing erosion, and broader macro headwinds. Any of these could cause actual Q1 FY27 Revenue or PAT to undershoot the Uniresearch projection.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_will_Concord_Biotech_declare_the_actual_Concord_Biotech_Q1_Results_FY27_data\"><\/span><strong>When will Concord Biotech declare the actual Concord Biotech Q1 Results FY27 data?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Concord Biotech will declare Q1 FY27 results after Q1 FY27 ends, typically shortly after Q1 FY27 ends. The board meeting date will be disclosed via NSE or BSE filings. Track live updates on the Univest Screener.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Concord Biotech Q1 Results FY27: Revenue Rs 193 Cr, PAT Rs 32 Cr (Uniresearch estimate). Analyst views, sector drivers and watchpoints inside.<\/p>\n","protected":false},"author":35,"featured_media":134203,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-133588","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782724035:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_title":["Concord Biotech Q1 Results FY27: Uniresearch Prediction and Analy"],"rank_math_description":["Concord Biotech Q1 Results FY27: Uniresearch projects Revenue Rs 193 Cr and PAT Rs 32 Cr. Growth drivers, risks and Uniresearch estimate inside."],"rank_math_focus_keyword":["Concord Biotech Q1 Results FY27"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["134203"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["22020"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Concord-Biotech-Q1-Results-FY27-What-to-Expect.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/133588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=133588"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/133588\/revisions"}],"predecessor-version":[{"id":134204,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/133588\/revisions\/134204"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/134203"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=133588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=133588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=133588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}